|
gptkbp:instanceOf
|
gptkb:chemical_compound
amphetamine
|
|
gptkbp:CASNumber
|
300-62-9
|
|
gptkbp:chemicalFormula
|
C9H13N
|
|
gptkbp:contains_functional_group
|
amphetamine
phenyl
|
|
gptkbp:discoveredBy
|
gptkb:Lazăr_Edeleanu
1887
|
|
gptkbp:eliminationHalfLife
|
9-14 hours
|
|
gptkbp:excretion
|
gptkb:kidney
|
|
gptkbp:has_stimulant_effect
|
yes
|
|
gptkbp:hasInChIKey
|
BHHGXPLMPWCGHP-UHFFFAOYSA-N
InChI=1S/C9H13N/c1-8(10)7-9-5-3-2-4-6-9/h2-6,8H,7,10H2,1H3
|
|
gptkbp:hasSMILES
|
CC(N)CC1=CC=CC=C1
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
1-phenyl-2-aminopropane
|
|
gptkbp:is_controlled_substance
|
yes
|
|
gptkbp:is_psychoactive
|
yes
|
|
gptkbp:IUPACName
|
1-phenylpropan-2-amine
|
|
gptkbp:legalStatus
|
gptkb:Class_B_(UK)
gptkb:Schedule_II_(Australia)
gptkb:Schedule_II_(US)
Schedule I (Canada)
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:molecularWeight
|
135.21 g/mol
|
|
gptkbp:parent
|
amphetamine
|
|
gptkbp:predecessor
|
amphetamine
|
|
gptkbp:PubChem_CID
|
3007
CHEBI:2679
CHEMBL1537
|
|
gptkbp:riskFactor
|
addiction
cardiovascular events
abuse potential
|
|
gptkbp:routeOfAdministration
|
oral
inhalation
intravenous
intranasal
|
|
gptkbp:sideEffect
|
anxiety
loss of appetite
increased heart rate
insomnia
dry mouth
|
|
gptkbp:synonym
|
amphetamine
2-aminopropylbenzene
alpha-methylphenethylamine
|
|
gptkbp:UNII
|
U77QF1TO7Z
|
|
gptkbp:used_as_medication
|
yes
|
|
gptkbp:usedFor
|
ADHD
narcolepsy
|
|
gptkbp:bfsParent
|
gptkb:P-ATO
|
|
gptkbp:bfsLayer
|
7
|